Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Syndax Pharmaceuticals

Evaluate

Thumbnail
March 28, 2023

Biotech heads towards big catalysts

The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.

December 15, 2022

Ash 2022 roundup

Evaluate Vantage's coverage of the Ash 2022 congress.

Article image
Vantage logo
December 14, 2022

Ash 2022 movers – Glycomimetics shakes off its sickle cell past

Meanwhile, there was bad blood between cell therapy players and their investors.

Article image
Vantage logo
December 11, 2022

Ash 2022 – Syndax and Kura face off

Duelling datasets on the companies’ rival menin inhibitors show each to have weaknesses and strengths.

Article image
Vantage logo
November 04, 2022

Ash 2022 preview – Affimed and Aptose score

In oncology settings outside multiple myeloma investors have picked two early winners.

Article image
Vantage logo
May 11, 2022

Opportunities arise for once-spurned partners

Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?

Article image
Vantage logo
December 15, 2021

Ash 2021 movers – IGM steals the show, for all the wrong reasons

At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.

Article image
Vantage logo
November 24, 2021

Kura death deals novel leukaemia mechanism a blow

Article image
Vantage logo
November 05, 2021

Ash 2021 preview – small increases and big falls

The early movers could point to a disappointing meeting.

Article image
Vantage logo
September 27, 2021

Incyte turns to in-licensing

Article image
Vantage logo
April 20, 2021

Syndax gets pulses races – but not in a good way

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up